Silvia Escribano Serrat Explores A Potential Role of EASIX as a Predictor of Refractoriness and Mortality in iTTP
Silvia Escribano Serrat, Research Fellow at Memorial Sloan Kettering Cancer Center, shared on LinkedIn:
”I am pleased to share this multicenter article on the potential role of EASIX as a predictor of refractoriness and mortality in iTTP.”
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a severe thrombotic microangiopathy caused by profound ADAMTS13 deficiency; although caplacizumab speeds platelet recovery, about 15% of patients remain refractory and may experience persistent endothelial or microvascular injury.
This study assessed whether the Endothelial Activation and Stress Index (EASIX) can track endothelial dysfunction and predict refractoriness or mortality in iTTP.
Read the full article here.
Article: EASIX, a new tool to predict response and refractoriness in immune-mediated thrombotic thrombocytopenic purpura
Authors: Silvia Escribano Serrat, María Queralt Salas, Cristina Pascual-Izquierdo, Manuel Fernández Villalobos, Inés Gómez-Seguí, Teresa Fidalgo, Marta Fernández Docampo, Jorge Martínez Nieto, Óscar Lamas, Miquel Lozano, Joan Cid, Paola Charry, Marc Pino, Patricia Molina, Blanca De Moner, Álex Ramos, Ana Belén Moreno-Castaño, Julia Martínez-Sánchez, Ginés Escolar, Maribel Díaz-Ricart
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 8, 2026, 05:51Dominika Jędrzejewska Akbaş Links Sleep Deprivation, Obesity, and Stroke
-
Jan 8, 2026, 05:42Rob Maloney: A Bruise that Did Not Go Away…
-
Jan 8, 2026, 05:33Matías J Alet on Treating Early Neurological Deterioration in Lacunar Stroke
-
Jan 8, 2026, 05:11Thomas Meinel Shares The English Stroke Guidelines 2026
-
Jan 8, 2026, 05:03Hilla Ben-Pazi: We Were Pleased to Receive a Grant from the Israeli Ministry of Economy
-
Jan 8, 2026, 04:24Nikhil Agrawal Breaks Down Perioperative Anticoagulation
-
Jan 8, 2026, 03:58Louise St Germain Bannon Appointed Interim Executive Director of ISTH
-
Jan 8, 2026, 03:47Wolfgang Miesbach on Fernando Corrales-Medina’s Team’s Latest Cross-Sectional Study on Haemophilia
-
Jan 8, 2026, 03:28Rick Matthews: Powerful Perspective from Erin and the NBCA Team